# US 2020/0390939 A1 · Collagen matrix or granulate blend of bone substitute material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390939 A1
- Document ID: US20200390939A1
- Status: Published application
- Kind: A1
- Application number: 16/899,921
- Filed: 2020-06-12
- Published: 2020-12-17
- Earliest claimed: 2019-06-14
- Assignees: Geistlich Pharma AG
- Applicants: Geistlich Pharma AG
- Inventors: Claudio ZIHLMANN; Michael BUFLER
- Web page: https://patentgrep.com/patent/US20200390939A1

## CPC

- A61L 27/46: with phosphorus-containing inorganic fillers
- A61L 2300/63: Crystals
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Collagen matrix granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface.

## Claims

### Claim 1

A collagen matrix comprising collagen and particles of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core such that the closed epitactically grown layer of nanocrystalline HAP has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface of the CAP/HAP bone substitute material.

### Claim 2 (depends on 1)

The collagen matrix of claim 1, wherein the collagen is a naturally crosslinked collagen that has been treated by an acidic solution.

### Claim 3 (depends on 1)

The collagen matrix of claim 1, wherein the collagen is a naturally crosslinked collagen that has been physically crosslinked by dehydrothermal treatment (DHT) or chemically crosslinked.

### Claim 4 (depends on 1)

The collagen matrix of claim 1, which comprises 60-97 w/w % bone substitute material and 3-40 w/w % collagen.

### Claim 5 (depends on 1)

The collagen matrix of claim 1, wherein the coarse areas between the individual clusters consist of platelets of HAP nanocrystals with individual platelet sizes of 0.2 to 5 μm as measured by scanning electron microscopy (SEM).

### Claim 6 (depends on 1)

The collagen matrix of claim 1, wherein the sintered CAP core essentially consists of α-tricalcium phosphate (α-TCP).

### Claim 7 (depends on 1)

The collagen matrix of claim 1, wherein the percentage of HAP in the particles of the biphasic CAP/HAP bone substitute material is 1.0 to 6.0% as measured by X-ray diffraction (XRD).

### Claim 8 (depends on 1)

The collagen matrix of claim 1, wherein the particles of the biphasic CAP/HAP bone substitute material have a size of 500 to 2000 μm.

### Claim 9 (depends on 1)

The collagen matrix of claim 1, which comprises:
particles of a CAP/HAP bone substitute material (A) comprising a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core such that the closed epitactically grown layer of nanocrystalline HAP has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface of the CAP/HAP bone substitute material, in a collagen matrix, wherein the % of HAP as measured by XRD is 1.0 to 6.0%, and
particles of a bone substitute material (B) selected from the group consisting of:
a biphasic CAP/HAP bone substitute material comprising a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the % of HAP as measured by XRD is 10 to 40%, and
a bone mineral derived from natural bone and retaining original crystal structure and mineral microstructure of natural bone, while having an organic impurity content below 150 parts per million and a protein content below 135 parts per million.

### Claim 10 (depends on 9)

The collagen matrix of claim 9, wherein
the % of HAP as measured by XRD is 1.0 to 6.0% in the particles of a CAP/HAP bone substitute material (A), and
the particles of a bone substitute material (B) are particles of a biphasic CAP/HAP bone substitute material comprising a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the % of HAP as measured by XRD is 30 to 40%.

### Claim 11 (depends on 1)

A process of preparing a putty material comprising the collagen matrix of claim 1, comprising
a) dispersing collagen fibres of a native naturally crosslinked collagen into an acidic solution at a pH from 2 to 5 to produce an acidic collagen slurry,
b) mixing and homogenizing the acidic collagen slurry with particles of abiphasic CAP/HAP bone substitute material comprising a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core such that the closed epitactically grown layer of nanocrystalline HAP has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface of the CAP/HAP bone substitute material to produce a collagen/CAP/HAP slurry,
c) freeze-drying the collagen/CAP/HAP slurry to produce a freeze-dried collagen/CAP/HAP slurry, and
d) sterilizing the freeze-dried collagen/CAP/HAP slurry by gamma-ray or X-ray irradiation, or ethylene oxide treatment.

### Claim 12 (depends on 11)

The process of claim 11, further comprising wet milling the acidic collagen slurry in a colloidal mill, blender mill or cutter mill.

### Claim 13

A granulate blend comprising a mixture of:
granules of a CAP/HAP bone substitute material (A) comprising a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core such that the closed epitactically grown layer of nanocrystalline HAP has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface of the CAP/HAP bone substitute material, in a collagen matrix, wherein the % of HAP as measured by XRD is 1.0 to 6.0%, and
granules of a bone substitute material (B) selected from the group consisting of:
a biphasic CAP/HAP bone substitute material comprising a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the % of HAP as measured by XRD is 10 to 40%, and
a bone mineral derived from natural bone and retaining original crystal structure and mineral microstructure of natural bone, while having an organic impurity content below 150 parts per million and a protein content below 135 parts per million.

### Claim 14 (depends on 13)

The granulate blend of claim 13, wherein
the % of HAP as measured by XRD is 1.0 to 6.0% in the granules of a CAP/HAP bone substitute material (A), and
the granules of a bone substitute material (B) are particles of a biphasic CAP/HAP bone substitute material comprising a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the % of HAP as measured by XRD is 30 to 40%.

### Claim 15 (depends on 13)

A granulate blend according to claim 13, wherein the w/w ratio of the particles of a CAP/HAP bone substitute material (A) to the particles of a bone substitute material (B) is from 0.1 to 9.9.

### Claim 16 (depends on 13)

The granulate blend of claim 13, wherein the granules have a diameter of 250 to 5000 μm.

### Claim 17 (depends on 1)

A method of promoting bone formation, bone regeneration and/or bone repair at a defect site in a subject by implanting the collagen matrix of claim 1 at the defect site, such that bone formation, bone regeneration and/or bone repair are promoted at the defect site.

### Claim 18 (depends on 13)

A method of promoting bone formation, bone regeneration and/or bone repair at a defect site in a subject by implanting the granulate blend of claim 13 at the defect site, such that bone formation, bone regeneration and/or bone repair are promoted at the defect site.

### Claim 19 (depends on 1)

A method of promoting osteogenic differentiation in a bone of a subject, comprising administering the collagen matrix of claim 1 to the bone of a subject, such that osteogenic differentiation is promoted in the bone of the subject.

### Claim 20 (depends on 13)

A method of promoting osteogenic differentiation in a bone of a subject, comprising administering the granulate blend of claim 13 to the bone of a subject, such that osteogenic differentiation is promoted in the bone of the subject.
